Global Respiratory Drugs Market (2018-2022), Projected to Register a CAGR of ~6%

Dublin, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The "Global Respiratory Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The respiratory drugs market will register a CAGR of almost 6% by 2022.

The high cost of respiratory disease management is expected to drive growth in the respiratory drugs market. The high cost of respiratory disease management has led the organizations such as the Lung Foundation Australia to demand support and funding from the government to reduce the cost.

Increase in incidence and prevalence of different types of respiratory diseases

Globally, respiratory diseases are a key cause of mortality and disease burden. Numerous types of respiratory diseases are on the rise, thereby pushing growth in the respiratory drugs market.

Patient non-adherence treatment

Non-adherence to treatment is particularly problematic for asthma and COPD disease management due to heterogeneous patient population. Device switching symptoms variability, and comorbidities are responsible for suboptimal adherence rates.

Competitive Landscape

With the presence of a considerable number of companies, this market appears to be fragmented. Several respiratory drug companies are focused on evolving new respiratory drugs with the entry of biologics and biosimilars for promising options for respiratory disease management.

Key Players

• AstraZeneca
• GlaxoSmithKline
• Merck
• Novartis

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 05: PIPELINE ANALYSIS

• Pipeline analysis

PART 06: MARKET SIZING

• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: MARKET SEGMENTATION BY TYPE OF RESPIRATORY DISEASE

• Segmentation by type of respiratory disease
• Comparison by type of respiratory disease
• Asthma - Market size and forecast 2017-2022
• COPD - Market size and forecast 2017-2022
• Allergic rhinitis - Market size and forecast 2017-2022
• Cystic fibrosis - Market size and forecast 2017-2022
• Idiopathic pulmonary fibrosis - Market size and forecast 2017-2022
• Other respiratory disorders - Market size and forecast 2017-2022
• Market opportunity by type of respiratory disease

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

• Geographical segmentation
• Regional comparison
• Americas - Market size and forecast 2017-2022
• EMEA - Market size and forecast 2017-2022
• APAC - Market size and forecast 2017-2022
• Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 13: MARKET TRENDS

• High cost of respiratory disease management
• Availability of biologics and biosimilars
• High use of complementary and alternative medicines
• Entry of generics

PART 14: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 15: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• GlaxoSmithKline
• Merck
• Novartis

For more information about this report visit https://www.researchandmarkets.com/research/qt93lq/global?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Respiratory Drugs